NEW YORK, NY / ACCESSWIRE / February 15, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
FCFS Shareholders Click Here: https://www.zlk.com/pslra-1/firstcash-inc-loss-submission-form?prid=23735&wire=1
OSH Shareholders Click Here: https://www.zlk.com/pslra-1/oak-street-health-inc-loss-submission-form?prid=23735&wire=1
FENC Shareholders Click Here: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=23735&wire=1
* ADDITIONAL INFORMATION BELOW *
FirstCash, Inc. (NASDAQ:FCFS)
This lawsuit is on behalf of all persons who purchased shares of FirstCash common stock between February 1, 2018 and November 12, 2021, both dates inclusive.
Lead Plaintiff Deadline: March 15, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/firstcash-inc-loss-submission-form?prid=23735&wire=1
According to the filed complaint, (a) FirstCash had made more than 3,600 loans to over 1,000 active-duty members of the military and their families at usurious interest rates above 36% - and often exceeding 200% - in violation of the Military Lending Act ("MLA") and the Consent Order Cash America had entered into with the Consumer Financial Protection Bureau (the "Order"); (b) FirstCash had failed to implement the remedial measures imposed by the Order; (c) FirstCash's financial results were, in substantial part, the product of the Company's violations of the MLA and the Order; and (d) as a result of the foregoing, FirstCash was exposed to a material undisclosed risk of legal, reputational and financial harm if the Company's violations of the MLA and the Order were ever publicly disclosed.
Oak Street Health, Inc. (NYSE:OSH)
OSH Lawsuit on behalf of: investors who purchased August 6, 2020 - November 8, 2021
Lead Plaintiff Deadline: March 14, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/oak-street-health-inc-loss-submission-form?prid=23735&wire=1
According to the filed complaint, during the class period, Oak Street Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Oak Street maintained relationships with third-party marketing agents likely to provoke law enforcement scrutiny; (2) Oak Street was providing free transportation to federal health care beneficiaries in a manner that would provoke law enforcement scrutiny; (3) these activities may be violations of the False Claims Act; (4) as such, Oak Street was at heightened risk of investigation by the U.S. Department of Justice and/or other federal law enforcement agencies; (5) as a result, Oak Street was subject to adverse impacts related to defense and settlement costs and diversion of management resources; and (6) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
FENC Lawsuit on behalf of: investors who purchased May 28, 2021 - November 26, 2021
Lead Plaintiff Deadline: April 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=23735&wire=1
According to the filed complaint, during the class period, Fennec Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Fennec had not successfully remediated, and overstated its efforts to remediate, issues with the manufacturing facility of its drug product manufacturer for PEDMARK, a new compound developed to reduce the incidence of hearing loss in children undergoing chemotherapy; (ii) as a result, the Food and Drug Administration likely to approve the Resubmitted Pedmark New Drug Application ("NDA"); (iii) accordingly, the regulatory and commercial prospects of the Resubmitted Pedmark NDA were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE : Levi & Korsinsky, LLP